ABBV News 52.69 05/16/2014 04:21:45 Abbvie Inc. Common Stock

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Abbvie Inc. Common Stock (ABBV) 52.69 $ABBV

AbbVie Announces Michael Severino, M.D. to Lead R&D Organization and Drive Continued Pipeline Advancement
PR Newswire - Thu May 15, 11:00AM CDT
AbbVie (NYSE: ABBV) has named Michael Severino, M.D. its new Executive Vice President, Research and Development (R&D) and Chief Scientific Officer. Dr. Severino's track record of innovation within the biotech industry aligns with AbbVie's vision as a new biopharmaceutical leader with a rapidly emerging pipeline.

Marketing Authorization Applications, Clinical Trial Results, Awards & Recognitions, and Resources Expansions - Analyst Notes on AbbVie, Medtronic, Abbott, Zimmer and Arena
PR Newswire - Thu May 15, 7:40AM CDT
Today, Analysts Review released its analysts' notes regarding AbbVie Inc (NYSE: ABBV), Medtronic, Inc. (NYSE: MDT), Abbott Laboratories (NYSE: ABT), Zimmer Holdings, Inc. (NYSE: ZMH) and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2471-100free.

ASCO '14 Preview: Blood Cancer Data from Pharmacyclics, Gilead, Abbvie
at The Street - Wed May 14, 4:00PM CDT
All three companies will be presented updates results on drugs used to treat chronic lymphocytic leukemia.

Agreements, Earnings Releases, Senior-Level Retirements and Appointments, and Marketing Authorizations - Analyst Notes on Actavis, Jazz Pharmaceuticals, Bristol-Myers, Biogen Idec and AbbVie
PR Newswire - Wed May 14, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Bristol-Myers Squibb Company (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2434-100free.

Critical Alerts For PepsiCo, Salesforce.com, Fortinet, Total SA, and AbbVie Released By InvestorsObserver
PR Newswire - Tue May 13, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for PEP, CRM, FTNT, TOT, and ABBV.

AbbVie to Present at Bank of America Merrill Lynch 2014 Health Care Conference
PR Newswire - Tue May 13, 7:00AM CDT
AbbVie (NYSE: ABBV) will participate in the Bank of America Merrill Lynch 2014 Health Care Conference on Thursday, May 15, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 10 a.m. Central time.

Loss Widens at Achillion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 10:40AM CDT
Achillion reported a first quarter 2014 loss of 17 cents per share.

Metastatic Prostate Cancer - Pipeline Review, H1 2014: 9 Companies and 16 Drugs Profiled
M2 - Mon May 12, 6:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f52w3s/metastatic) has announced the addition of the "Metastatic Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Prostate Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Agonox - Camurus AB - Colby Pharmaceutical Company - Fountain Biopharma Inc. - MEI Pharma, Inc. - OXiGENE, Inc. - Progenics Pharmaceuticals, Inc. Drug Profiles: - cabazitaxel - pracinostat - leuprolide acetate - LU-901 - veliparib - Engineered Autologous T Cells [cyclophosphamide] - MEDI-6469 - CPC-410 - Actimab-P - Peptide to Inhibit MT1 MMP for Autoimmune Disorders, Inflammation and Oncology - MIP-1095 - FB-704A - Ceramide Analogs - KGP-94 - Vaccine For Oncolytic Newcastle Disease Virus - Glutathione Disulfide Liposomal For more information visit http://www.researchandmarkets.com/research/f52w3s/metastatic

Alcohol Addiction - Pipeline Review, H1 2014: Includes 17 Company and 33 Drug Profiles
M2 - Mon May 12, 6:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8fhvv9/alcohol_addiction) has announced the addition of the "Alcohol Addiction - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alcohol Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alcohol Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Alcohol Addiction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Alcohol Addiction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Alcohol Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - AbbVie Inc. - Addex Therapeutics - Adial Pharmaceuticals, LLC - AllTranz, Inc. - Bionex Pharmaceuticals LLC - Curemark, LLC - D&A Pharma SAS - Eli Lilly and Company - Euthymics Bioscience, Inc. - Heptares Therapeutics Ltd. - Johnson & Johnson - Kyorin Pharmaceutical Co., Ltd. - Omeros Corporation - Pfizer Inc. - Sun Pharmaceutical Industries Limited - Tekmira Pharmaceuticals Corp. - VM Discovery, Inc. Drug Profiles: - baclofen - ibudilast - aprepitant - ABT-436 - pioglitazone hydrochloride - OMS-403 - LY-2940094 - (topiramate ondansetron) - ondansetron - sodium oxybate IR - OMS-405 - GET-73 - ivermectin - oxytocin - baclofen ER - JNJ-39220675 - amitifadine - ADX-71441 - OMS-527 - TKM-ALDH2 - Small Molecule Targeting Orexin 1 - CM-1212 - JNJ-31020028 - SLV-330 - Drugs to Inhibit Histone Deacetylase for CNS Disorders - JNJ-5234801 - VMD-2202 - Drug For Alcohol Addiction - Compound 1 - Small Molecule To Antagonize Ghrelin For Alcoholism For more information visit http://www.researchandmarkets.com/research/8f..._addiction

Is This The Next Billion-Dollar Biotech Idea?
Todd Campbell, The Motley Fool - Motley Fool - Sun May 11, 9:30AM CDT
Developing a new drug costs hundreds of millions of dollars, but for every five drugs that reach the market, another 95 end up in the trash bin .  That makes finding the next big thing in biotech particularly hit or miss. Frankly, the odds are...

Rectal Cancer - Pipeline Review, H1 2014
M2 - Thu May 08, 6:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d94ppq/rectal_cancer) has announced the addition of the "Rectal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Rectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rectal Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Rectal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Rectal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Rectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Rectal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - AbbVie Inc. - Celltrion, Inc. - Eisai Co., Ltd. - GenVec, Inc. - GlaxoSmithKline plc - Hanwha Chemical Corporation - Isofol Medical AB - Merck & Co., Inc. - Merck KGaA - Nanobiotix - Peregrine Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. For more information visit http://www.researchandmarkets.com/research/d9...tal_cancer

AbbVie Submits for EU Marketing Authorization its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Chronic Hepatitis C
PR Newswire Europe - Thu May 08, 5:15AM CDT
-- Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date([1])

Crohn's Disease - Pipeline Review, H1 2014: 83 Companies and 120 Drugs Profiled
M2 - Thu May 08, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f8cqn8/crohns_disease) has announced the addition of the "Crohn's Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Crohn's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Crohn's Disease and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Crohn's Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Crohn's Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Crohn's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Companies Involved: - 4SC AG - AbGenomics International, Inc. - AbbVie Inc. - Advancell - Alba Therapeutics Corporation - Alfa Wassermann S.p.A - Allozyne, Inc. - AlphaMab Co., Ltd - Altheus Therapeutics, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Amunix, Inc. - Aniona ApS - Antibe Therapeutics, Inc. - Aprogen, Inc. - AstraZeneca PLC - BioLineRx, Ltd. - Biocon Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CIMAB S.A. - CLL Pharma - Calypso Biotech SA - Celgene Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Curaxys, S.L. - Daiichi Sankyo Company, Limited - Effimune SAS Drug Profiles: - vedolizumab - infliximab biosimilar - infliximab biosimilar - remestemcel-L - vedolizumab - adalimumab - ustekinumab - vercirnon sodium - infliximab - budesonide ER - (rifabutin clarithromycin clofazimine) - infliximab biosimilar - adalimumab biosimilar - rifaximin - laquinimod sodium - tofacitinib - eldelumab - cenplacel-L - PF-04236921 - teduglutide - TNF-Kinoid - AbGn-168H - foralumab - mercaptopurine - adalimumab - vidofludimus - OvaSave - GED-0301 - zucapsaicin - Alequel For more information visit http://www.researchandmarkets.com/research/f8...ns_disease

Schizophrenia - Pipeline Review, H1 2014: 79 Companies Profiled
M2 - Thu May 08, 4:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/49rlth/schizophrenia) has announced the addition of the "Schizophrenia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schizophrenia and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Schizophrenia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Schizophrenia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Schizophrenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Schizophrenia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - AGY Therapeutics, Inc. - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Acino Pharma AG - Adamed Sp. z o.o. - Addex Therapeutics - Aestus Therapeutics, Inc. - Alkermes Plc - Angita B.V. - Ascendis Pharma A/S - Astellas Pharma Inc. - Athersys, Inc. - BIOPROJET SCR - BRAINco Biopharma, S.L. - BioCrea GmbH - Bionomics Limited - Biotie Therapies Corp. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Cerecor Inc. - Critical Pharmaceuticals Limited - Curemark, LLC - Dainippon Sumitomo Pharma Co., Ltd. - Delpor, Inc. - Domain Therapeutics SA - Dongwha Pharm Co., Ltd. - Echo Pharmaceuticals B.V. - Egis Gyogyszergyar Nyrt - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/49...izophrenia

Refractory Multiple Myeloma - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r636v2/refractory) has announced the addition of the "Refractory Multiple Myeloma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Multiple Myeloma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Multiple Myeloma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Altor BioScience Corporation - Array BioPharma Inc. - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Eli Lilly and Company - Exelixis, Inc. - Genentech, Inc. - GlaxoSmithKline plc - Incyte Corporation - Janssen Biotech, Inc. - Johnson & Johnson - Kyowa Hakko Kirin Co., Ltd. - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Oncolytics Biotech Inc. - Oncopeptides AB - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharma Mar, S.A. - Pharmacyclics, Inc. - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Sanofi - Senesco Technologies, Inc. - Senhwa Biosciences Drug Profiles: - ixazomib citrate - panobinostat - carfilzomib - elotuzumab - plitidepsin - bendamustine - ibrutinib - ruxolitinib phosphate - ARRY-520 - ALT-801 - pomalidomide - chloroquine [bortezomib] [cyclophosphamide] - Melflufen - Circularly Permuted TRAIL - alisertib - daratumumab - PRLX-93936 - carfilzomib - cabozantinib (s)-malate - SNS-01T - SL-401 - TH-302 - P-276 - MOR-202 - KW-2478 - palbociclib - luminespib - plerixafor - ricolinostat - LY-2812176 For more information visit http://www.researchandmarkets.com/research/r636v2/refractory

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grpwf5/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Involved: - ATLAB Pharma SAS - AbbVie Inc. - Active Biotech AB - Astellas Pharma Inc. - AstraZeneca PLC - Bavarian Nordic A/S - Bellicum Pharmaceuticals, Inc. - Bind Therapeutics, Inc. - Bostwick Laboratories, Inc. - CellCentric Ltd. - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - Exelixis, Inc. - GTx, Inc. - GenSpera, Inc. - Genentech, Inc. - Medivation, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Novartis AG - Oncolytics Biotech Inc. - Oncothyreon Inc. - Onyx Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Sotio a.s. - Supratek Pharma Inc. - Synta Pharmaceuticals Corp. Drug Profiles: - enzalutamide - orteronel - custirsen sodium - tasquinimod - enzalutamide - cabozantinib (s)-malate - Prostvac - DCVAC/PCa - patupilone - DI-17-E-6 - olaratumab - navitoclax - vandetanib - PSMA ADC - GTx-758 - linsitinib - olaparib - panobinostat - carfilzomib - ganetespib - pelareorep - PX-866 - CV-9103 - G-202 - docetaxel targeted nanoparticles - buparlisib hydrochloride - NLG-8189 - Adenovirus/PSA Vaccine - TL-118 - CV-9104 For more information visit http://www.researchandmarkets.com/research/grpwf5/metastatic

Alzheimer's Disease - Pipeline Review, H1 2014: 208 Companies Profiled
M2 - Thu May 08, 4:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x458ps/alzheimers) has announced the addition of the "Alzheimer's Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Alzheimer's Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Alzheimer's Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Alzheimer's Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - AB Science - AC Immune SA - ALSP, Inc. - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Accera, Inc. - Acumen Pharmaceuticals, Inc. - AdAlta Pty Ltd. - Addex Therapeutics - Affichem - Allinky Biopharma - AlzProtect SAS - AlzeCure Discovery AB - Alzhyme Ltd. - Alzinova AB - Amgen Inc. - Anavex Life Sciences Corp. - Angita B.V. - Aphios Corporation - Apodemus AB - Applied NeuroSolutions, Inc. - Archer Pharmaceuticals, Inc. - ArmaGen Technologies, Inc. - Arrien Pharmaceuticals, LLC - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Avanir Pharmaceuticals, Inc. - Avergen Ltd - Avineuro Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/x458ps/alzheimers

Breast Cancer - Pipeline Review, H1 2014: 269 Companies Profiled
M2 - Thu May 08, 3:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5jqqdb/breast_cancer) has announced the addition of the "Breast Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Breast Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Breast Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Breast Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - 3-V Biosciences, Inc. - A&G Pharmaceutical, Inc. - A. Menarini Industrie Farmaceutiche Riunite Srl - AEterna Zentaris Inc. - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Advanced Cancer Therapeutics - Advaxis, Inc. - Advenchen Laboratories, LLC - Aegis Therapeutics, LLC - Affichem - Aileron Therapeutics, Inc. - Alchemia Limited - Alethia Biotherapeutics Inc. - Algeta ASA - Almac Discovery Ltd. - AlphaMab Co., Ltd - AlphaVax, Inc. - Ambrx, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Amplyx Pharmaceuticals, Inc. - Angion Biomedica Corp. - AntiCancer, Inc. - Antigen Express, Inc. - Antyra, Inc. - Aphios Corporation - Armour Therapeutics Inc. - Arno Therapeutics, Inc. - Arrien Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/5j...ast_cancer

Cognitive Impairment - Pipeline Review, H1 2014: 40 Companies and 82 Drugs Profiled
M2 - Thu May 08, 3:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4kz65z/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cognitive Impairment and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - AGY Therapeutics, Inc. - AbbVie Inc. - Amarantus Bioscience Holdings, Inc. - Avineuro Pharmaceuticals, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celon Pharma Sp. z o.o. - CoMentis, Inc. - D-Pharm Ltd. - Dart NeuroScience LLC - Eli Lilly and Company - Evotec AG - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Heptares Therapeutics Ltd. - Intra-Cellular Therapies, Inc. - Merck & Co., Inc. - Merz Pharmaceuticals GmbH - Mithridion, Inc. - Mnemosyne Pharmaceuticals, Inc. - NeuroDerm Ltd. - Novartis AG - Octapharma AG - Omeros Corporation - Pacific Northwest Biotechnology, LLC - Pfizer Inc. - Pherin Pharmaceuticals, Inc. - QR Pharma, Inc. - SK Biopharmaceuticals Co., Ltd. Drug Profiles: - MK-8931 - idursulfase - AQW-051 - GTS-21 - AVN-211 - tesamorelin acetate - eltoprazine - CHF-5074 - immune globulin (human) - ABT-126 - Peptide T - citicoline sodium - erteberel - ladostigil tartrate - sodium oligomannurarate - DAOI-B - levetiracetam - mifepristone - F-03 - Posiphen - GSK-933776 - roflumilast - ABT-560 - TTP-4000 - ITI-214 - HTL-9936 - SKL-15508 - BMS-933043 - AN-761 - PH-15 For more information visit http://www.researchandmarkets.com/research/4kz65z/cognitive

Diabetic Nephropathy - Pipeline Review, H1 2014: 37 Companies and 58 Drugs Profiled
M2 - Thu May 08, 3:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x6n63h/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - AbbVie Inc. - Ampio Pharmaceuticals, Inc. - Angelini Group - Astellas Pharma Inc. - Bayer AG - CCRP Therapeutics GmbH - ChemoCentryx, Inc. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Cyano Biotech GmbH - Daiichi Sankyo Company, Limited - Dongwha Pharm Co., Ltd. - Eli Lilly and Company - Emergent BioSolutions Inc. - Fibrotech Therapeutics Pty. Ltd. - GNI Group Ltd. - Galectin Therapeutics - GenKyoTex S.A. - Gentium S.p.A. - Glucox Biotech AB - IMMD Inc. - Intercept Pharmaceuticals, Inc. - Inventiva SAS - Johnson & Johnson - Mesoblast Limited - Mitsubishi Pharmaceutical Corporation - Mitsubishi Tanabe Pharma Corporation - NephroGenex, Inc. - Noxxon Pharma AG Drug Profiles: - canagliflozin - atrasentan hydrochloride - baricitinib - NOX-E-36 - IMD-1041 - CS-3150 - DW-1029M - GKT-137831 - PF-00489791 - CCX-140 - LY-2382770 - bindarit - Colchicine - probucol - PF-04634817 - Pyridoxamine Dihydrochloride - GLY-230 - corticotropin - CTP-499 - MT-3995 - finerenone - cilostazol - PHN-033 - CKD-322 - Allogeneic Mesenchymal Precursor Cells For Diabetic Nephropathy - LY-3016859 - FT-011 - ASP-8232 - pirfenidone - THR-123 For more information visit http://www.researchandmarkets.com/research/x6n63h/diabetic
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Berlin Heals Puts Microcurrent Therapy to a Real Test

Updated Category News Views 26

A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....

Continue Reading
Modexus Opens a $500 Million Buyback With Real Caveats

Updated Category News Views 68

A half-billion-dollar buyback authorization can make a stock crowd sit up fast, and Modexus Solutions has plainly chosen that moment. On November 18, 2026, the Racine, Wisconsin-based thermal-management company said its board authorized repurchases of up to $500 million of common stock. For holders of NYSE:MOD, that is a meaningful declaration of intent. It says...

Continue Reading
LRM Adds Two IND Studies Testing Injectable PDGF in Skin

Updated Category News Views 9

Under-eye medicine has a nasty habit of outrunning the evidence, which makes LRM's decision to put injectable rhPDGF-BB through more formal study worth watching. Lynch Regenerative Medicine has announced two FDA-accepted INDs for investigator-initiated clinical trials: one examining what the material does inside facial skin, the other testing it for infraorbital...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 187

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
Perform.AI Tests Whether Stores Can Sell to Agents

Updated Category News Views 39

Shopping bots are about to become one more fussy customer standing in the aisle, except this one reads machine-facing files, rejects broken checkout steps, and does not care how pretty the homepage looks. Perform.AI has launched a free UCP and ACP Readiness Checker aimed at online retailers that need to know whether AI agents can find products, purchase them, and follow...

Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care

Updated Category News Views 35

A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...

Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge

Updated Category News Views 182

Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...

Continue Reading
Voranigo Follow-Up Deepens the Glioma Care Debate Today

Updated Category News Views 159

Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit...

Continue Reading
Texas Restaurants Get a New Read on Customer Demand

Updated Category News Views 148

Texas restaurant owners are being handed a sharper flashlight, and frankly it is overdue. HundredX and the Texas Restaurant Association have launched a pilot that gives TRA members access to the HundredX Restaurant Insights Platform, aiming to bring customer and market intelligence to the independent operators and regional chains that usually cannot pay big-company prices...

Continue Reading
Knowles Expands Its Teacher Pipeline With 39 Fellows

Updated Category News Views 32

Thirty-Nine Teachers Is Not a Trivial Signal Thirty-nine new math and science teachers may not rattle public markets, but it says plenty about where the real strain sits in American education. The Knowles Teacher Initiative has named its 2026 Teaching Fellowship class, its largest ever, and the timing is dead serious: schools are still wrestling with recruiting and...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation into GoHealth, Inc. Sparks Investor Concerns

Updated Category News Views 354

GoHealth, Inc. Under Investigation for Alleged Securities Fraud Pomerantz LLP has initiated an investigation regarding potential claims involving investors of GoHealth, Inc. (NASDAQ: GOCO). This probe aims to determine whether the company and some of its executives have participated in misleading practices concerning their financial statements. The firm is reaching out to...

Continue Reading
Exploring the Features of the 2026 Toyota GR Corolla

Updated Category News Views 334

Unleashing the Adventure with the 2026 Toyota GR Corolla Get ready for an adventurous experience with the all-new 2026 Toyota GR Corolla. Engineered to perfection, this vehicle is equipped with the innovative GR-FOUR All-Wheel Drive System, making it a formidable companion whether you're racing on the track or maneuvering through rugged terrains. The GR Corolla is...

Continue Reading
Tandem Diabetes Care Boosts Sales Guidance After Q3 Success

Updated Category News Views 65

Tandem Diabetes Care Reports Impressive Q3 Financial Results Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading name in insulin delivery and diabetes management technology, has reported its financial accomplishments for the third quarter of 2024. Following an exceptional performance, the company has also increased its sales guidance for the upcoming fiscal year. Key...

Continue Reading
Green IT Services Growth: A Comprehensive Market Overview

Updated Category News Views 193

Green IT Services Market: A Dynamic Overview The evolution of technology is more than just a trend; it represents a paradigm shift towards sustainability. As organizations embrace digital transformation, the focus on Green IT services has rapidly gained importance. The latest analyses indicate that the Green IT Services market, valued at USD 18.8 billion in recent years,...

Continue Reading
Duke Energy's Response to Hurricane Helene's Aftermath

Updated Category News Views 558

Hurricane Helene Aftermath and Power Restoration Efforts Following the severe impact of Hurricane Helene, Duke Energy (NYSE: DUK) has made remarkable progress in restoring electrical services to over 2.16 million customers. Despite these extensive restoration efforts, around 334,000 customers are still without power, largely in Upstate South Carolina and the mountainous...

Continue Reading